--- title: Publications | SiMSen-Seq ctDNA research papers description: Browse 30-plus peer-reviewed publications featuring SiMSen-Seq and Simsen's ctDNA methods, with direct links to the journals and full-text PDFs. --- [Skip to the main content.](https://simsendiagnostics.com/evidence-publications#main-content) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com?hsLang=en) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com?hsLang=en) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) Search [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLQDAHCxJNP%2Bj85dgswAJrFKndQua4UEIXQ3On1qD8QDvUQvsx82uiS1Q5yoRDbR9Tt7JCNTKZyNYVaBtTFHZ5AnCLajg9JAuWHysM2O0Ff3rOGyKlrE2CiWFj40NdccVkr29%2Bhu8bSJu9lE7WJqIVdd4R9A45U%2F%2FMQFE8sUt7UxpLha4DYTGikNY4aQcU4kx2lNY50&webInteractiveContentId=412216133822&portalId=25734893&hsLang=en) Toggle Menu Search Toggle Menu [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLQDAHCxJNP%2Bj85dgswAJrFKndQua4UEIXQ3On1qD8QDvUQvsx82uiS1Q5yoRDbR9Tt7JCNTKZyNYVaBtTFHZ5AnCLajg9JAuWHysM2O0Ff3rOGyKlrE2CiWFj40NdccVkr29%2Bhu8bSJu9lE7WJqIVdd4R9A45U%2F%2FMQFE8sUt7UxpLha4DYTGikNY4aQcU4kx2lNY50&webInteractiveContentId=412216133822&portalId=25734893&hsLang=en) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) [For clinical trials Pharma and CROs Validate MRD endpoints, cut trial-arm cost, build EU regulatory readiness. Design a trial assay →](https://simsendiagnostics.com/solutions-trials?hsLang=en) [For research and labs Translational oncology See signal in paediatric and early-stage samples your current platform misses. Send samples or run SiMSen-Seq in-house. See the signal →](https://simsendiagnostics.com/solutions-research?hsLang=en) [For clinics Premium oncology monitoring Detect minimal residual disease ahead of imaging. Logistics across the EU, UK and EEA. Detect relapse earlier →](https://simsendiagnostics.com/solutions-clinic?hsLang=en) [Home](https://simsendiagnostics.com?hsLang=en) / [Evidence](https://simsendiagnostics.com/evidence-hub?hsLang=en) / Publications Evidence # The science behind what you can *detect*. Peer-reviewed papers, case studies and white papers, framed around what the data means for your trial, your laboratory and your patients. Read the overview, then go straight to the source. #### Type All #### Disease area All #### Access All 31 publications Sorted by: newest first Peer-reviewed Free to read 2025 ### Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile Shows that patient-specific (tumour-informed) panels enable sensitive ctDNA detection in rhabdomyosarcoma regardless of the tumour's genetic profile. Rahmqvist I, Dahlstrand Rudin A, Mellstrom E, Ibrahim RR, Andersson D, Pujol Calderon F, Ordqvist Redfors A, Rostamzadeh N, Franssila W, Karlsson C, Zetterlund F, Khashan R, Frostdahl H, Osterlund T, Ek T, Fagman H, Stahlberg A, Dalin M. Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile. *npj Precis. Onc.* 9, 327 (2025). [Read on publisher site (DOI)](https://doi.org/10.1038/s41698-025-01147-6) [Download PDF](https://simsendiagnostics.com/hubfs/Patient-specific%20sequencing%20panels%20enable%20sensitive%20circulating%20tumor%20DNA%20analysis%20in%20rhabdomyosarcoma%20independent%20of%20genetic%20profile.pdf?hsLang=en) Peer-reviewed Free to read 2025 ### Digital sequencing is improved by using structured unique molecular identifiers Demonstrates that structured unique molecular identifiers improve the accuracy of digital sequencing. Micallef, P., Santamaría, M.L., Escobar, M. et al. Digital sequencing is improved by using structured unique molecular identifiers. *Genome Biol* 26, 37 (2025). [Read on publisher site (DOI)](https://doi.org/10.1186/s13059-025-03504-x) Peer-reviewed Free to read 2025 ### Evaluation of automatic cell free DNA extraction metrics using different blood collection tubes Compares blood collection tubes for their effect on automated cell-free DNA extraction metrics. Andersson, D., Kristiansson, H., Luna Santamaría, M. et al. Evaluation of automatic cell free DNA extraction metrics using different blood collection tubes. *Sci Rep* 15, 19364 (2025). [Read on publisher site (DOI)](https://doi.org/10.1038/s41598-025-03508-4) [Download PDF](https://simsendiagnostics.com/hubfs/Evaluation%20of%20automatic%20cell%20free%20DNA%20extraction%20metrics%20using%20different%20blood%20collection%20tubes.pdf?hsLang=en) Peer-reviewed Free to read 2025 ### Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements Shows personalised ultrasensitive ctDNA monitoring can reduce imaging needs in metastatic breast cancer. Mouhanna P, Ståhlberg A, Andersson D, et al. Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements. *Int J Cancer*. 2025;156(8):1509-1517.  [Read on publisher site (DOI)](https://doi.org/10.1002/ijc.35292) [Download PDF](https://simsendiagnostics.com/hubfs/Integration%20of%20personalised%20ultrasensitive%20ctDNA%20monitoring.pdf?hsLang=en) Peer-reviewed Free to read 2024 ### Principles of digital sequencing using unique molecular identifiers Review of the principles behind digital sequencing with unique molecular identifiers. Andersson D, Kebede FT, Escobar M, Osterlund T, Stahlberg A. Principles of digital sequencing using unique molecular identifiers. *Molecular Aspects of Medicine*, Volume 96, 2024 [Read on publisher site (DOI)](https://doi.org/10.1016/j.mam.2024.101253) [Download PDF](https://simsendiagnostics.com/hubfs/Principles%20of%20digital%20sequencing.pdf?hsLang=en) Peer-reviewed Free to read 2024 ### Personalized circulating tumor DNA analysis for sensitive disease monitoring and detection of relapse in neuroblastoma Personalised ctDNA analysis detects relapse and monitors disease in neuroblastoma. Rahmqvist, I., Engström, E., Mellström, E. et al. Personalized circulating tumor DNA analysis for sensitive disease monitoring and detection of relapse in neuroblastoma. *Biomark Res* 12, 148 (2024). [Read on publisher site (DOI)](https://doi.org/10.1186/s40364-024-00688-5) [Download PDF](https://simsendiagnostics.com/hubfs/ClinStudiesPdfs/Personalized%20circulating%20tumor%20DNA%20analysis%20for%20sensitive%20disease%20monitoring%20and%20detection%20of%20relapse%20in%20neuroblastoma.pdf?hsLang=en) Peer-reviewed Free to read 2024 ### Mechanistic basis of atypical TERT promoter mutations Explains the mechanism behind atypical TERT promoter mutations. Elliott, K., Singh, V.K., Bäckerholm, A. et al. Mechanistic basis of atypical TERT promoter mutations. *Nat Commun* 15, 9965 (2024). [Read on publisher site (DOI)](https://doi.org/10.1038/s41467-024-54158-5) [Download PDF](https://simsendiagnostics.com/hubfs/ClinStudiesPdfs/Mechanistic%20basis%20of%20atypical%20TERT%20promoter%20mutations.pdf?hsLang=en) Peer-reviewed Free to read 2024 ### Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis ALK-driven relapsed/refractory neuroblastoma patients had long-lasting responses to lorlatinib, tracked by ctDNA. Torben Ek, Raghda R. Ibrahim, Hartmut Vogt, Kleopatra Georgantzi, Catarina Träger, Jennie Gaarder, Anna Djos, Ida Rahmqvist, Elisabeth Mellström, Fani Pujol-Calderón, Christoffer Vannas, Lina Hansson, Henrik Fagman, Diana Treis, Susanne Fransson, Tobias Österlund, Tzu-Po Chuang, Bronte Manouk Verhoeven, Anders Ståhlberg, Ruth H. Palmer, Bengt Hallberg, Tommy Martinsson, Per Kogner, Martin Dalin; Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis. *Cancer Research Communications* 1 September 2024; 4 (9): 2553–2564. [Read on publisher site (DOI)](https://doi.org/10.1158/2767-9764.CRC-24-0338) [Download PDF](https://simsendiagnostics.com/hubfs/ClinStudiesPdfs/Long-Lasting%20Response%20to%20Lorlatinib%20in%20Patients.pdf?hsLang=en) Peer-reviewed Free to read 2024 ### gamma-delta T cells in human colon adenocarcinomas comprise mainly Vd1, Vd2, and Vd3 cells with distinct phenotype and function Characterises gamma-delta T-cell subsets in human colon adenocarcinomas. Rodin, W., Szeponik, L., Rangelova, T. et al. γδ T cells in human colon adenocarcinomas comprise mainly Vδ1, Vδ2, and Vδ3 cells with distinct phenotype and function. *Cancer Immunol Immunother* 73, 174 (2024). [Read on publisher site (DOI)](https://doi.org/10.1007/s00262-024-03758-7) [Download PDF](https://simsendiagnostics.com/hubfs/ClinStudiesPdfs/%CE%B3%CE%B4%20T%20cells%20in%20human%20colon%20adenocarcinomas.pdf?hsLang=en) Peer-reviewed Free to read 2024 ### Treatment monitoring of a patient with synchronous metastatic angiosarcoma and breast cancer using ctDNA Case report: ctDNA used to monitor treatment in a patient with synchronous angiosarcoma and breast cancer. Vannas C, Escobar M, Osterlund T, Andersson D, Mouhanna P, Soomagi A, Molin C, Wennergren D, Fagman H, Stahlberg A. Treatment monitoring of a patient with synchronous metastatic angiosarcoma and breast cancer using ctDNA. *Int J Mol Sci.* 2024. [Read on publisher site (DOI)](https://doi.org/10.3390/ijms25074023) [Download PDF](https://simsendiagnostics.com/hubfs/ClinStudiesPdfs/Treatment%20Monitoring%20of%20a%20Patient.pdf?hsLang=en) Peer-reviewed Free to read 2024 ### Ultrasensitive sequencing of STR markers utilizing unique molecular identifiers and the SiMSen-Seq Applies SiMSen-Seq and UMIs to ultrasensitive forensic STR marker sequencing. Sidstedt M, Gynna AH, Kiesler KM, Jansson L, Steffen CR, Hakansson J, Johansson G, Osterlund T, Bogestal Y, Tillmar A, Radstrom P, Stahlberg A, Vallone PM, Hedman J. Ultrasensitive sequencing of STR markers utilizing unique molecular identifiers and the SiMSen-Seq. *Forensic Sci Int Genet*. 2024. [Read on publisher site (DOI)](https://doi.org/10.1016/j.fsigen.2024.103047) [Download PDF](https://simsendiagnostics.com/hubfs/ClinStudiesPdfs/Ultrasensitive%20sequencing%20of%20STR%20markers.pdf?hsLang=en) Peer-reviewed Free to read 2024 ### Digital RNA sequencing using unique molecular identifiers enables ultrasensitive RNA mutation analysis Extends UMI-based digital sequencing to ultrasensitive RNA mutation analysis. Luna Santamaria M, Andersson D, Parris TZ, Helou K, Osterlund T, Stahlberg A. Digital RNA sequencing using unique molecular identifiers enables ultrasensitive RNA mutation analysis. *Commun Biol*. 2024. [Read on publisher site (DOI)](https://doi.org/10.1038/s42003-024-05955-7) [Download PDF](https://simsendiagnostics.com/hubfs/Digital%20RNA%20sequencing%20using.pdf?hsLang=en) Peer-reviewed Free to read 2023 ### Tissue specificity of oncogenic BRAF targeted to lung and thyroid through a shared lineage factor Cancer-biology study of how oncogenic BRAF drives lung and thyroid tumours via a shared lineage factor. Schoultz E, Liang S, Carlsson T, Filges S, Stahlberg A, Fagman H, Wiel C, Sayin V, Nilsson M. Tissue specificity of oncogenic BRAF targeted to lung and thyroid through a shared lineage factor. *iScience*. 2023. [Read on publisher site (DOI)](https://doi.org/10.1016/j.isci.2023.107071) [Download PDF](https://simsendiagnostics.com/hubfs/Tissue%20specificity%20of%20oncogenic.pdf?hsLang=en) Peer-reviewed Free to read 2022 ### Extracellular vesicle DNA from human melanoma tissues contains cancer-specific mutations Finds cancer-specific mutations in extracellular-vesicle DNA from melanoma tissue. Crescitelli R, Filges S, Karimi N, Urzi O, Alonso-Agudo T, Stahlberg A, Lotvall J, Lasser C, Olofsson Bagge R. Extracellular vesicle DNA from human melanoma tissues contains cancer-specific mutations. *Front Cell Dev Biol*. 2022. [Read on publisher site (DOI)](https://doi.org/10.3389/fcell.2022.1028854) [Download PDF](https://simsendiagnostics.com/hubfs/Extracellular%20vesicle%20DNA.pdf?hsLang=en) Peer-reviewed Free to read 2022 ### Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response ctDNA persistence during neoadjuvant treatment predicts poor tumour response in breast cancer. Zhou Q, et al. Persistence of ctDNA in patients with breast cancer during neoadjuvant treatment is a significant predictor of poor tumor response. *Clin Cancer Res*. 2022. [Read on publisher site (DOI)](https://doi.org/10.1158/1078-0432.CCR-21-3231) [Download PDF](https://simsendiagnostics.com/hubfs/Persistence%20of%20ctDNA%20in%20Patients%20with%20Breast%20Cancer.pdf?hsLang=en) Peer-reviewed Free to read 2022 ### UMIErrorCorrect and UMIAnalyzer: Software for Consensus Read Generation, Error Correction, and Visualization Using Unique Molecular Identifiers Introduces the UMIErrorCorrect and UMIAnalyzer software for UMI-based sequencing analysis. Osterlund T, Filges S, Johansson G, Stahlberg A. UMIErrorCorrect and UMIAnalyzer: software for consensus read generation, error correction, and visualization using unique molecular identifiers. *Clin Chem*. 2022.  [Read on publisher site (DOI)](https://doi.org/10.1093/clinchem/hvac136) [Download PDF](https://simsendiagnostics.com/hubfs/UMIErrorCorrect%20and%20UMIAnalyzer.pdf?hsLang=en) Peer-reviewed Free to read 2021 ### Digital quantification of chemical oligonucleotide synthesis errors Uses digital sequencing to quantify errors introduced during chemical oligonucleotide synthesis. Filges S, Mouhanna P, Stahlberg A. Digital quantification of chemical oligonucleotide synthesis errors. *Clin Chem*. 2021.  [Read on publisher site (DOI)](https://doi.org/10.1093/clinchem/hvab136) [Download PDF](https://simsendiagnostics.com/hubfs/Digital%20Quantification%20of%20Chemical.pdf?hsLang=en) Peer-reviewed Free to read 2021 ### Monitoring Circulating Tumor DNA During Surgical Treatment in Patients with Gastrointestinal Stromal Tumors Monitors ctDNA during surgery in gastrointestinal stromal tumours (GIST). Johansson G, Berndsen M, Lindskog S, Osterlund T, Fagman H, Muth A, Stahlberg A. Monitoring circulating tumor DNA during surgical treatment in patients with gastrointestinal stromal tumors. *Mol Cancer Ther.* 2021. [Read on publisher site (DOI)](https://doi.org/10.1158/1535-7163.MCT-21-0403) [Download PDF](https://simsendiagnostics.com/hubfs/Monitoring%20Circulating%20Tumor%20DNA%20During.pdf?hsLang=en) Peer-reviewed Free to read 2021 ### The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma Phase 2 PEMDAC trial of pembrolizumab plus entinostat in metastatic uveal melanoma. Ny L, Jespersen H, Karlsson J, Alsen S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. *Nat Commun*. 2021. [Read on publisher site (DOI)](https://doi.org/10.1038/s41467-021-25332-w) [Download PDF](https://simsendiagnostics.com/hubfs/The%20PEMDAC%20phase%202.pdf?hsLang=en) Peer-reviewed Free to read 2020 ### Dynamic ctDNA evaluation of a patient with BRAFV600E metastatic melanoma demonstrates the utility of ctDNA for disease monitoring and tumor clonality analysis Case study using dynamic ctDNA to monitor BRAFV600E metastatic melanoma and analyse clonality. Vannas C, Bjursten S, Filges S, Fagman H, Stahlberg A, Levin M. Dynamic ctDNA evaluation of a patient with BRAFV600E metastatic melanoma demonstrates the utility of ctDNA for disease monitoring and tumor clonality analysis. *Acta Oncol*. 2020. [Read on publisher site (DOI)](https://doi.org/10.1080/0284186X.2020.1802064) [Download PDF](https://simsendiagnostics.com/hubfs/Dynamic%20ctDNA%20evaluation.pdf?hsLang=en) Peer-reviewed Free to read 2020 ### Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers Applies UMIs to ultrasensitive DNA immune-repertoire sequencing. Johansson G, Kaltak M, Rimniceanu C, Singh AK, Lycke J, Malmestrom C, Huhn M, Vaarala O, Cardell S, Stahlberg A. Ultrasensitive DNA immune repertoire sequencing using unique molecular identifiers. *Clinical Chemistry*, Volume 66, Issue 9. 2020. [Read on publisher site (DOI)](https://doi.org/10.1093/clinchem/hvaa159) [Download PDF](https://simsendiagnostics.com/hubfs/Ultrasensitive%20DNA%20Immune%20Repertoire%20Sequencing.pdf?hsLang=en) Peer-reviewed Free to read 2020 ### Response to BRAF/MEK inhibition in A598\_T599insV BRAF mutated melanoma Case report of response to BRAF/MEK inhibition in a rare BRAF-insertion melanoma. Bjursten S, Vannas C, Filges S, Puls F, Pandita A, Fagman H, Stahlberg A, Levin M. Response to BRAF/MEK inhibition in A598\_T599insV BRAF mutated melanoma. *Case Rep Oncol*. 2020. [Read on publisher site (DOI)](https://doi.org/10.1159/000504291) [Download PDF](https://simsendiagnostics.com/hubfs/Response%20to%20BRAFMEK.pdf?hsLang=en) Peer-reviewed Free to read 2019 ### Multilaboratory assessment of a new reference material for quality assurance of cell-free tumor DNA measurements Multilaboratory validation of a new reference material for cell-free tumour DNA quality assurance. He HJ, Stein EV, Konigshofer Y, Forbes T, Tomson FL, Garlick R, Yamada E, Godfrey T, Abe T, Tamura K, et al. Multilaboratory assessment of a new reference material for quality assurance of cell-free tumor DNA measurements. *J Mol Diagn*. 2019. [Read on publisher site (DOI)](https://doi.org/10.1016/j.jmoldx.2019.03.006) [Download PDF](https://simsendiagnostics.com/hubfs/Multilaboratory%20Assessment.pdf?hsLang=en) Peer-reviewed Free to read 2019 ### Detection of circulating tumor DNA in plasma: a potential biomarker for esophageal adenocarcinoma ctDNA in plasma as a potential biomarker for esophageal adenocarcinoma. Egyud M, Tejani M, Pennathur A, Luketich J, Sridhar P, Yamada E, Stahlberg A, Filges S, Krzyzanowski P, Jackson J, et al. Detection of circulating tumor DNA in plasma: a potential biomarker for esophageal adenocarcinoma. *Ann Thorac Surg*. 2019. [Read on publisher site (DOI)](https://doi.org/10.1016/j.athoracsur.2019.04.004) [Download PDF](https://simsendiagnostics.com/hubfs/Detection%20of%20Circulating%20Tumor%20DNA.pdf?hsLang=en) Peer-reviewed Free to read 2019 ### Impact of polymerase fidelity on background error rates in next-generation sequencing with unique molecular identifiers/barcodes Assesses how polymerase fidelity affects background error rates in UMI/barcode sequencing. Filges S, Yamada E, Stahlberg A, Godfrey T. Impact of polymerase fidelity on background error rates in next-generation sequencing with unique molecular identifiers/barcodes. *Sci Rep*. 2019. [Read on publisher site (DOI)](https://doi.org/10.1038/s41598-019-39762-6) [Download PDF](https://simsendiagnostics.com/hubfs/Impact%20of%20Polymerase%20Fidelity.pdf?hsLang=en) Peer-reviewed Free to read 2019 ### Considerations and quality controls when analyzing cell-free tumor DNA Practical considerations and quality controls for cell-free tumour DNA analysis. Johansson G, Andersson D, Filges S, Li J, Muth A, Godfrey TE, Stahlberg A. Considerations and quality controls when analyzing cell-free tumor DNA. *Biomol Detect Quantif*. 2019. [Read on publisher site (DOI)](https://doi.org/10.1016/j.bdq.2018.12.003) [Download PDF](https://simsendiagnostics.com/hubfs/Considerations%20and%20quality%20controls.pdf?hsLang=en) Peer-reviewed Free to read 2019 ### Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer Plasma ctDNA as a disease-monitoring tool in head and neck cancer. Egyud M, Sridhar P, Devaiah A, Yamada E, Saunders S, Stahlberg A, Filges S, Krzyzanowski P, Kalatskaya I, Jiao W, et al. Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer. *Head Neck.* 2019. [Read on publisher site (DOI)](https://doi.org/10.1002/hed.25563) [Download PDF](https://simsendiagnostics.com/hubfs/Plasma%20circulating%20tumor%20DNA.pdf?hsLang=en) Peer-reviewed Free to read 2018 ### Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers Links elevated pyrimidine-dimer formation to promoter mutation hotspots in UV-exposed cancers. Elliott K, Bostrom M, Filges S, Lindberg M, Van den Eynden J, Stahlberg A, Clausen AR, Larsson E. Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers. *PLoS Genet*. 2018. [Read on publisher site (DOI)](https://doi.org/10.1371/journal.pgen.1007849) [Download PDF](https://simsendiagnostics.com/hubfs/Elevated%20pyrimidine%20dimer.pdf?hsLang=en) Peer-reviewed Free to read 2017 ### Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature Defines a context-specific mutational signature behind recurrent promoter mutations in melanoma. Fredriksson NJ, Elliott K, Filges S, Van den Eynden J, Stahlberg A, Larsson E. Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature. *PLoS Genet*. 2017. [Read on publisher site (DOI)](https://doi.org/10.1371/journal.pgen.1006773) [Download PDF](https://simsendiagnostics.com/hubfs/Recurrent%20promoter%20mutations.pdf?hsLang=en) Peer-reviewed Free to read 2017 ### Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing The foundational SiMSen-Seq method: multiplexed PCR barcoding for ultrasensitive mutation detection. Stahlberg A, Krzyzanowski PM, Egyud M, Filges S, Stein L, Godfrey T. Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing. *Nat Protoc*. 2017;12(4):664-682. [Read on publisher site (DOI)](https://doi.org/10.1038/nprot.2017.006) Peer-reviewed Free to read 2016 ### Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing Earlier SiMSen-Seq method paper: multiplexed PCR barcoding for sensitive mutation detection in liquid biopsies. Stahlberg A, Krzyzanowski PM, Jackson JB, Egyud M, Stein L, Godfrey TE. Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing. *Nucleic Acids Res*. 2016. [Read on publisher site (DOI)](https://doi.org/10.1093/nar/gkw224) [Download PDF](https://simsendiagnostics.com/hubfs/Simple%20multiplexed%20PCR-based.pdf?hsLang=en) No publications match those filters. Try clearing one of them. USING THE EVIDENCE ## Can't find evidence for your indication? Tell our scientific team what you are working on and we will point you to the most relevant data, including unpublished work we can share under agreement. [Start a conversation](https://simsendiagnostics.com/start-a-conversation?hsLang=en)   ### Why do most papers go to the publisher rather than a pdf here? Peer-reviewed papers are copyright of the publisher, so we link to the version of record via its DOI, which is permanent and authoritative. Where a paper is open access, we also offer the PDF directly.   ### Which materials can I download straight away? Our own white papers, posters, case studies and one-pagers are hosted here. Some white papers ask for a few details first so we can stay in touch.   ### Can I cite these in my own work? Yes. Each publication shows a full AMA/Vancouver citation with DOI or PMID, ready to copy. For our own posters, case studies and similar documents - get in touch with us at [inbox@simsendiagnostics.com](mailto:inbox@simsendiagnostics.com) and we will sort it. Talk to us ### Speak to our scientific team. A real human, in CET/CEST time zone, who has run samples like yours. [inbox@simsendiagnostics.com →](mailto:inbox@simsendiagnostics.com) [Request a conversation →](https://simsendiagnostics.com/start-a-conversation?hsLang=en)   ![full_lockup_white_CMYK kopia](https://simsendiagnostics.com/hs-fs/hubfs/full_lockup_white_CMYK%20kopia.png?width=166&height=45&name=full_lockup_white_CMYK%20kopia.png) **Visiting and postal address:** Pepparedsleden 1 431 53 Mölndal, Sweden **Shipping address:** c/o AstraZeneca R&D Mölndal Pepparedsleden 3 431 53 Mölndal, Sweden PLATFORM PLATFORM - [Platform overview](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) SOLUTIONS SOLUTIONS - [For clinical trials](https://simsendiagnostics.com/solutions-trials) - [For research and labs](https://simsendiagnostics.com/solutions-research) - [For clinics](https://simsendiagnostics.com/solutions-clinic) - [Solutions overview](https://simsendiagnostics.com/solutions-overview) COMPANY COMPANY - [About](https://simsendiagnostics.com/company-about) - [News](https://simsendiagnostics.com/news) - [Team](https://simsendiagnostics.com/company-team) - [Contact](https://simsendiagnostics.com/company-contact) - [Privacy policy](https://simsendiagnostics.com/legal-privacy-policy) - [Cookie Policy](https://simsendiagnostics.com/legal-cookie-policy) - [Terms of use](https://simsendiagnostics.com/legal-terms-of-use) © 2026 Simsen Diagnostics AB, All rights reserved. [Linkedin](https://www.linkedin.com/company/simsendiagnostics) Return to top